早期乳腺癌诊疗进展  

Advances in the diagnosis and treatment of early breast cancer

作　　者：叶松青[1] 王瑞娟[1] 黄湘秦 YE Songqing;WANG Ruijuan;HUANG Xiangqin(Department of Breast Surgery,Fujian Provincial Hospital,Fuzhou 350001,P.R.China)

机构地区：[1]福建省立医院乳腺外科,福州350001

出　　处：《中国普外基础与临床杂志》2024年第9期1033-1037,共5页Chinese Journal of Bases and Clinics In General Surgery

摘　　要：实体瘤新疗法的进步,通常是由晚期向早期逐渐过渡的。Luminal型乳腺癌早期治疗,已经进入“内分泌治疗+”的时代,治疗时长和强度的强化以及联合靶向治疗,多基因检测仍与临床参数共存。对HER2阳性早期乳腺癌,新辅助治疗改变了治疗的流程,需进行(新)辅助精准强化及降阶梯的探索,“新辅助改变辅助,早期治疗影响复发治疗”。三阴性乳腺癌早期治疗,虽曾一度呈现出纷繁复杂的“百家争鸣”之态,但如今的治疗策略已远非仅聚焦于那3个阴性标志物的简单应对,核心在于精准诊断,分类而治!笔者现就早期乳腺癌诊疗进展进行总结,以期为临床医师的实际应用提供有价值的参考。The progress of new therapies for solid tumors usually gradually transitions from late stage to early stage.Early treatment of Luminal breast cancer has entered the era of“endocrine therapy+”,with the strengthening of treatment duration and intensity,combined with targeted therapy and multi-gene detection,which still coexist with clinical parameters.For HER2-positive early breast cancer,neoadjuvant therapy has changed the treatment process,requiring exploration of precise strengthening and de-escalation of neoadjuvant therapy.“Neoadjuvant therapy changes adjuvant therapy,and early treatment affects recurrence treatment”.Although the early treatment of triple-negative breast cancer once showed a complicated state of“a hundred schools of thought contend”,today’s treatment strategy is far from focusing on the simple respond of those three negative markers.The core lies in precise diagnosis and classification for treatment!This article summarizes the progress of early breast cancer diagnosis and treatment,in order to provide valuable reference for clinicians’practical application.

关 键 词：早期乳腺癌 辅助治疗 免疫治疗 幸存者关怀 

分 类 号：R737.9[医药卫生—肿瘤]